Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.

  PMID 34654806 · PMC8519947 · Nature communications · 2021 · 7 claims · 4 setups

  Has reproduction · 100

  Pathway-based signatures derived from on-treatment tumor specimens (PASS-ON) are highly predictive of response to anti-PD1 blockade in metastatic melanoma, achieving validation AUCs of 0.85–0.89.

  metastatic bulk

• Gene Dosage Analysis on the Single-Cell Transcriptomes Linking Cotranslational Protein Targeting to Metastatic Triple-Negative Breast Cancer.

  PMID 34577617 · PMC8472593 · Pharmaceuticals (Basel, Switzerland) · 2021 · 7 claims · 5 setups

  Has reproduction · 53

  A computational framework integrating independently measured CNV (DNA sequencing) and single-cell RNA-seq from the same patients identifies recurrent concordant copy number gain and gene upregulation (CNG-UP) events and functional modules at the single-cell level.

  metastatic top breast tnbc single-cell functional mutational

• Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning.

  PMID 36611079 · PMC9825621 · NPJ precision oncology · 2023 · 7 claims · 8 setups

  Has reproduction

  Tabular ML classifiers (TabNet, XGBoost, LightGBM) trained on tumor-only-derived features achieve state-of-the-art somatic vs germline classification, with AUC>94% on TCGA holdout and AUC>85% on metastatic melanoma.

  tcga metastatic tumor-only whole-exome wes copy-number

• Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.

  PMID 33425745 · PMC7793995 · Frontiers in oncology · 2020 · 7 claims · 6 setups

  Has reproduction · 48

  The CD8A-high/IDO1-high colon cancer subtype (group IV*) has the worst survival despite high CD8 infiltrates.

  tcga-coad ncbi-geo colon c57bl bulk gene immune

• Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

  PMID 36450752 · PMC9712620 · Nature communications · 2022 · 8 claims · 8 setups

  Has reproduction · 70

  AR enhancer/chromatin binding usage is highly heterogeneous between primary prostate tumors, with <5% of all AR binding sites shared by half of tumors analyzed.

  prostate normal ar+ pca chip-seq rna-seq massively

• The use of laser capture microscopy in proteomics research--a review.

  PMID 15502248 · PMC3839334 · Disease markers · 2004 · 8 claims · 8 setups

  Full-text index only

  LCM allows purification of specific, histologically defined cell populations from heterogeneous tissue for downstream proteomic analysis

  breast prostate esophageal head maldi-tof automated two-dimensional

• Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.

  PMID 19763266 · PMC2740864 · PloS one · 2009 · 8 claims · 8 setups

  Full-text index only

  Androgen treatment alters the whole-cell proteome of LNCaP prostate cancer cells

  lncap androgen prostate itraq mudpit immunoblot

• Diagnostic proteomics: serum proteomic patterns for the detection of early stage cancers.

  PMID 15258335 · PMC3851082 · Disease markers · 2003 · 8 claims · 8 setups

  Full-text index only

  Proteomic pattern analysis of serum mass spectra, without identifying the underlying proteins, can distinguish cancer patients from healthy controls with high sensitivity and specificity.

  serum frozen ig-depleted clinical seldi-tof maldi lc-ms

• The current state of proteomics in GI oncology.

  PMID 19104933 · PMC3045515 · Digestive diseases and sciences · 2009 · 8 claims · 8 setups

  Full-text index only

  More than 130 exploratory proteomic studies have defined candidate biomarkers in serum, GI fluids, or cancer tissue for GI oncology

  serum laser-capture-microdissected seldi-ms 2-de antibody